April 2nd 2024
Jonathan Zager, MD, spoke about the use of observation vs systemic immunotherapy to treat patients with stage IIIA and IIIB melanoma.
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Tumor-Infiltrating Lymphocyte Therapy Advances Into Melanoma
View More
Diffuse Hepatic Infiltration by Metastatic Melanoma
Melanoma of the skin is the 19th most common malignant neoplasm worldwide, with 287,723 new cases estimated for 2018 and metastatic melanoma accounting for 4% of all new cases. In recent years, the prognosis of this stage has undergone a dramatic transformation with the advent of immunotherapy and BRAF/MEK targeted therapy.
Dr. Anna Pavlick on Dendritic Cells vs Montanide in Melanoma Patients in Remission
June 20th 2019Cancer Network spoke with Anna Pavlick, MD, of NYU Langone Health, on the results of a phase II study of poly-ICLC matured dendritic cells for NY-ESO-1 and Mean-A peptide vaccination compared with Montanide.
Investigators Are Assessing an Experimental Interleukin-2 Drug in Patients With Metastatic Melanoma
June 5th 2019A phase III study comparing the efficacy and safety of nivolumab plus an experimental interleukin-2–based drug vs nivolumab alone in patients with metastatic melanoma is now enrolling patients.
Will Adjuvant Pembrolizumab Be an Effective Therapy for High-Risk Melanoma?
June 4th 2019Investigators are now enrolling patients for a phase III trial, KEYNOTE-716, to assess the efficacy and safety of adjuvant pembrolizumab in adult and pediatric patients with surgically resected high-risk stage II melanoma.
ILLUMINATE 301 Will Study Experimental Immunotherapy for Patients With Advanced Melanoma
June 4th 2019Investigators are now enrolling for a phase III trial testing the experimental immunotherapy tilsotolimod plus ipilimumab in patients with advanced melanoma who have progressed on anti–PD-1 therapy.